WO2021162525A1 - 히드록시유레아를 포함하는 염증 반응 억제용 약학 조성물 - Google Patents
히드록시유레아를 포함하는 염증 반응 억제용 약학 조성물 Download PDFInfo
- Publication number
- WO2021162525A1 WO2021162525A1 PCT/KR2021/001910 KR2021001910W WO2021162525A1 WO 2021162525 A1 WO2021162525 A1 WO 2021162525A1 KR 2021001910 W KR2021001910 W KR 2021001910W WO 2021162525 A1 WO2021162525 A1 WO 2021162525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- pharmaceutical composition
- correction
- under rule
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 60
- 230000028709 inflammatory response Effects 0.000 title claims description 12
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 title abstract description 94
- 229960001330 hydroxycarbamide Drugs 0.000 title abstract description 94
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 206010040047 Sepsis Diseases 0.000 claims abstract description 72
- 241000700605 Viruses Species 0.000 claims abstract description 70
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims abstract description 35
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 25
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 19
- 244000309459 oncolytic virus Species 0.000 claims abstract description 17
- 206010029379 Neutrophilia Diseases 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 241000711573 Coronaviridae Species 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 37
- 241000700618 Vaccinia virus Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 239000003443 antiviral agent Substances 0.000 claims description 21
- 239000003242 anti bacterial agent Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 12
- 208000004235 neutropenia Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 229960002182 imipenem Drugs 0.000 claims description 8
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 8
- -1 nelifavir Chemical compound 0.000 claims description 8
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 8
- 241000712079 Measles morbillivirus Species 0.000 claims description 7
- 241000700562 Myxoma virus Species 0.000 claims description 7
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 7
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 6
- 241000709687 Coxsackievirus Species 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 241000991587 Enterovirus C Species 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 6
- 241000125945 Protoparvovirus Species 0.000 claims description 6
- 241000702263 Reovirus sp. Species 0.000 claims description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 6
- 241001632234 Senecavirus Species 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 6
- 229960003752 oseltamivir Drugs 0.000 claims description 6
- 229960000329 ribavirin Drugs 0.000 claims description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims description 4
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
- 108010053950 Teicoplanin Proteins 0.000 claims description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- KDNSSKPZBDNJDF-UHFFFAOYSA-N [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid Chemical compound C12=NC(N)=NC=C2N=CN1CC1(OCP(O)(O)=O)CC1 KDNSSKPZBDNJDF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004748 abacavir Drugs 0.000 claims description 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 4
- 229960004150 aciclovir Drugs 0.000 claims description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 4
- 229960001997 adefovir Drugs 0.000 claims description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 4
- 229960002118 asunaprevir Drugs 0.000 claims description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 4
- 229950002782 besifovir Drugs 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002100 cefepime Drugs 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 4
- 229960004828 ceftaroline fosamil Drugs 0.000 claims description 4
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims description 4
- 229960000484 ceftazidime Drugs 0.000 claims description 4
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 4
- 229960004755 ceftriaxone Drugs 0.000 claims description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 4
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 4
- 229960005338 clevudine Drugs 0.000 claims description 4
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims description 4
- 229960005449 daclatasvir Drugs 0.000 claims description 4
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims description 4
- 229960005107 darunavir Drugs 0.000 claims description 4
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 4
- 229960001418 dasabuvir Drugs 0.000 claims description 4
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002542 dolutegravir Drugs 0.000 claims description 4
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 4
- 229960000895 doripenem Drugs 0.000 claims description 4
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 4
- 229960003804 efavirenz Drugs 0.000 claims description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 4
- 229960000980 entecavir Drugs 0.000 claims description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 4
- 229960002049 etravirine Drugs 0.000 claims description 4
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004396 famciclovir Drugs 0.000 claims description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 229960004710 maraviroc Drugs 0.000 claims description 4
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000689 nevirapine Drugs 0.000 claims description 4
- 229960001084 peramivir Drugs 0.000 claims description 4
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 4
- 229960002814 rilpivirine Drugs 0.000 claims description 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 4
- 229960000311 ritonavir Drugs 0.000 claims description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
- 229960002063 sofosbuvir Drugs 0.000 claims description 4
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims description 4
- 229960001608 teicoplanin Drugs 0.000 claims description 4
- 229960005311 telbivudine Drugs 0.000 claims description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 4
- 229960001355 tenofovir disoproxil Drugs 0.000 claims description 4
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims description 4
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 4
- 229960003962 trifluridine Drugs 0.000 claims description 4
- 208000007089 vaccinia Diseases 0.000 claims description 4
- 229940093257 valacyclovir Drugs 0.000 claims description 4
- 229960003165 vancomycin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 4
- 229960001028 zanamivir Drugs 0.000 claims description 4
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 4
- 229960002555 zidovudine Drugs 0.000 claims description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 abstract description 33
- 239000000203 mixture Substances 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 15
- 244000005700 microbiome Species 0.000 abstract description 15
- 230000008718 systemic inflammatory response Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 abstract description 8
- 210000002865 immune cell Anatomy 0.000 abstract description 6
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 230000037456 inflammatory mechanism Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 44
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 16
- 108020004440 Thymidine kinase Proteins 0.000 description 14
- 241000700646 Vaccinia virus WR Species 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 12
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 102000006601 Thymidine Kinase Human genes 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 229940061367 tamiflu Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010037888 Rash pustular Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000029561 pustule Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 201000010740 swine influenza Diseases 0.000 description 3
- 230000005727 virus proliferation Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000036581 Vaccinia virus Western Reserve Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000881059 Vaccinia virus Wyeth Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 108010065183 antilipopolysaccharide antibodies Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the pharmaceutical use of hydroxyurea, which exerts an effect of suppressing an inflammatory response such as systemic inflammatory response syndrome or sepsis by modulating immune cells such as neutrophils.
- Systemic inflammatory response syndrome refers to a condition in which a severe inflammatory response occurs throughout the body. Clinically, symptoms include fever in which the body temperature rises above 38°C or hypothermia below 36°C, respiratory rate increases to more than 24 beats per minute (tachypnea), heart rate greater than 90 beats per minute (tachycardia), an increase in white blood cell count in blood tests, or When two or more symptoms of a significant decrease are present, it is defined as systemic inflammatory response syndrome. Systemic inflammatory responses are also induced by sepsis, trauma, lacerations, and pancreatitis. In particular, when this systemic inflammatory response syndrome is caused by an infection with a microorganism, it is called sepsis.
- Sepsis refers to a symptom in which an infection occurs when a tissue or organ is injured, and the immune response to it is strong enough to threaten life in the body. Sepsis is caused by an inflammatory immune response to infection. In general, these infections are bacterial, but sepsis can also be caused by spores, viral infections, and the like. Sepsis is a primary infection through the organs of the lungs, brain, urethra, skin, and abdomen. If you are too young or too old, or if your immunity is weakened by cancer or diabetes, you may be vulnerable to sepsis. Sepsis can cause irreversible damage to the body by inducing a serious inflammatory reaction throughout the body, and the mortality rate reaches 30%, and 30 million patients worldwide occur every year.
- Such sepsis is mainly treated by supplying fluids and administration of antibiotics.
- various anti-inflammatory substances and immunomodulators have been tried as therapeutic agents to suppress the hyperinflammatory response of sepsis.
- attempts have been made to treat sepsis using immunomodulators such as corticosteroids, anti-endotoxin antibodies, TNF antagonists, and IL-1 receptor antagonists. did not get the desired result.
- an object of the present invention is to provide a pharmaceutical composition for preventing, alleviating or treating systemic inflammatory response syndrome or sepsis by inhibiting the systemic inflammatory response.
- one aspect of the present invention provides a pharmaceutical composition for preventing, alleviating or treating systemic inflammatory response syndrome or sepsis comprising hydroxyurea as an active ingredient.
- Hydroxyurea an active ingredient of the pharmaceutical composition of the present invention, can regulate the activity of neutrophils, which are immune cells related to the inflammatory mechanism in the subject, and side effects caused by systemic inflammatory reactions that can be induced by exposure to microorganisms such as bacteria or viruses or to protect an individual from a condition. Therefore, when the pharmaceutical composition of the present invention is administered to an individual suffering from a systemic inflammatory response, it is possible to prevent, alleviate or treat systemic inflammatory response syndrome or sepsis in the individual, and ultimately significantly increase the survival rate of the individual.
- composition according to the present invention may be useful for preventing, alleviating or treating neutropenia that may appear when exposed to microorganisms such as bacteria or viruses, and the virus includes not only pathogenic viruses such as influenza or coronavirus, but also tumors. Viruses for therapeutic purposes, such as lytic viruses, are included.
- HU hydroxyurea
- Figure 2 confirms the survival rate according to the HU treatment in mice induced sepsis using bacterial LPS (lipopolysaccharides).
- Figure 3 confirms the survival rate according to the HU treatment in mice induced sepsis using the bacterial LPS.
- Figure 4 confirms the survival rate according to the HU treatment in mice induced sepsis using the Western Reserve vaccinia virus (Vaccinia virus Western Reserve strain, WR virus, 1 ⁇ 10 5 pfu).
- Figure 5 shows the number of virus particles in the blood of mice treated with HU after inducing sepsis using the Western Reserve vaccinia virus.
- FIG. 6 is a view showing the survival rate according to HU treatment in mice induced by sepsis using Western Reserve vaccinia virus (1 ⁇ 10 5 pfu and 1 ⁇ 10 7 pfu).
- FIG. 7 is a photograph of staining liver and lung tissues after administration of HU or G-CSF to mice induced by sepsis using Western Reserve vaccinia virus.
- Figure 8 shows the experimental schedule for confirming the effect of HU in the influenza virus (Influenza virus) induced sepsis model.
- Figure 9 confirms the survival rate according to Tamiflu and / or HU treatment in mice induced sepsis using influenza virus.
- Figure 10 is an observation of changes in body weight according to Tamiflu and / or HU treatment in mice induced sepsis using influenza virus.
- CC 50 represents the concentration at which about 50% of the cytotoxic reaction occurs
- EC 50 represents the concentration at which the effect of the drug is exhibited by about 50%.
- FIG. 12 is a photograph confirming the occurrence of skin rash and pustules according to HU treatment in monkeys induced with systemic inflammatory syndrome using Western Reserve vaccinia virus.
- FIG. 14 shows the measurement of the number of virus particles in blood after HU treatment in monkeys induced with systemic inflammatory syndrome using Western Reserve vaccinia virus.
- ANC neutrophil count
- WBC whole blood cell
- ALC absolute lymphocyte count according to HU treatment in monkeys induced with systemic inflammatory syndrome using Western Reserve vaccinia virus.
- FIG. 16 confirms that, when infected with various types of viruses other than SARS-CoV-2, the absolute neutrophil count (ANC) value is higher in patients with “Fatal” compared to patients with “Non-Fatal”.
- ANC absolute neutrophil count
- FIG. 17 is a result of analyzing blood samples of patients who died early during oncolytic virus infection, showing that ANC increased rapidly in patients who died early.
- 19 is a photograph of staining lung tissue after administration of HU or G-CSF to mice induced by sepsis using Western Reserve vaccinia virus.
- 21 is an observation of changes in survival rate and ANC in mice induced by sepsis using influenza virus.
- FIG. 22 is a photograph confirming the occurrence of skin rash and pustules according to HU treatment in monkeys induced with systemic inflammatory syndrome using vaccinia virus VV tk-.
- Figure 23 shows the measurement of absolute neutrophil count (ANC) and virus particle count according to HU treatment in monkeys induced with systemic inflammatory syndrome using Western Reserve vaccinia virus.
- the present invention is for preventing, alleviating or treating systemic inflammatory response syndrome (SIRS) or sepsis, comprising a compound of the following structural formula 1 (hydroxyurea) or a pharmaceutically acceptable salt thereof as an active ingredient.
- SIRS systemic inflammatory response syndrome
- a pharmaceutical composition is provided.
- the pharmaceutical composition can be effectively used for septic shock as well as sepsis.
- the hydroxyurea may be included in the pharmaceutical composition in the form of a commercialized drug containing hydroxyurea.
- Commercially available pharmaceuticals containing the hydroxyurea component may be, but are not limited to, Hydroxyurea®, Hydrea®, DroxiaTM, MylocelTM, and Siklos® hydrin capsules.
- the pharmaceutical composition may be administered by injection, and may have a formulation for intravenous administration, for example, a liquid formulation.
- the hydroxyurea may be administered in a dose of 0.1 mg/kg/day to 90 mg/kg/day.
- the dosage of the hydroxyurea is 0.1 mg/kg/day to 90 mg/kg/day, 1 mg/kg/day to 80 mg/kg/day, 5 mg/kg/day to 70 mg/kg /day, 10 mg/kg/day to 60 mg/kg/day, or 20 mg/kg/day to 50 mg/kg/day may be administered.
- the hydroxyurea is continuously maintained at 10 uM to 500 uM, 50 uM to 400 uM, 80 uM to 300 uM, 100 uM to 200 uM, and 120 uM to 150 uM in the blood.
- the blood concentration value may be appropriately determined according to the severity of systemic inflammatory response syndrome or sepsis and the patient's response rate.
- systemic inflammatory response syndrome refers to a condition in which a severe inflammatory response occurs throughout the body. Fever in which the body temperature rises above 38°C or hypothermia below 36°C, respiratory rate increases to more than 24 beats per minute (tachypnea), heart rate greater than 90 beats per minute (tachycardia), increases or decreases significantly in white blood cell count on blood tests When two or more symptoms are present, it is defined as systemic inflammatory response syndrome (SIRS).
- SIRS systemic inflammatory response syndrome
- the systemic inflammatory response syndrome may be accompanied by an inflammatory response that appears upon exposure to bacteria or viruses.
- systemic inflammatory responses are also induced by trauma or burns. In particular, when this systemic inflammatory response syndrome is caused by an infection with a microorganism, it is called sepsis.
- the systemic inflammatory response syndrome is accompanied by an inflammatory response that appears when exposed to a virus, and the virus is influenza virus, coronavirus, adenovirus, herpes simplex virus, Measles virus, Lentivirus, Retrovirus, Cytomegalovirus, baculovirus, Reovirus, Adeno-associated virus, Myxoma virus, Vesicular stomatitis virus, Poliovirus, Newcastle disease virus, Parvovirus, Coxsackie virus, Senecavirus , may be any one or more selected from the group consisting of vaccinia virus (Vaccinia virus) and poxvirus (Poxvirus).
- the virus may be in wild-type or mutated form.
- the virus may also be an oncolytic virus, for example a recombinant vaccinia virus in which the thymidine kinase (TK) gene is deleted.
- the oncolytic virus may be a recombinant vaccinia virus (OTS-412) in which a thymidine kinase gene is deleted and a mutated Herpes simplex virus type 1 Thymidine Kinase gene is inserted. .
- the oncolytic virus may be a recombinant vaccinia virus (VVtk-) in which the granulocyte-macrophage colony stimulating factor (GM-CSF) and ⁇ -galactosidase genes are not inserted and the thymidine kinase gene is deleted.
- VVtk- granulocyte-macrophage colony stimulating factor
- ⁇ -galactosidase genes are not inserted and the thymidine kinase gene is deleted.
- the oncolytic virus may be a recombinant vaccinia virus in which a thymidine kinase (TK) gene is deleted and a human GM-CSF or human G-CSF gene is inserted.
- TK thymidine kinase
- the term “septicemia” refers to a disease in which a severe inflammatory reaction occurs throughout the body.
- the sepsis may be accompanied by an inflammatory response that appears upon exposure to bacteria or viruses.
- sepsis can cause serious organ damage in an individual due to an abnormality of the individual's immune system due to microbial infection.
- immune cells such as neutrophils, macrophages, and monocytes are activated.
- septic shock is a condition in which the death rate is increased due to the occurrence of circulatory, cellular, and metabolic abnormalities due to worsening of sepsis symptoms. If timely and appropriate treatment is not provided, shock or death can occur.
- sepsis refers to a case where the diagnostic criteria for systemic inflammatory response syndrome are satisfied in a patient with suspected or proven infection.
- systemic inflammatory response syndrome is characterized by a body temperature >38°C or ⁇ 36°C, heart rate >90 beats/min, respiration rate >20 beats/min or PaC02 ⁇ 32 mmHg, and white blood cell count >12,000 cells/mm 3 or It is defined as a case where two or more of ⁇ 4,000 cells/mm 3 or undifferentiated form >10% are satisfied.
- the sepsis may be caused by infection with a microorganism, and the microorganism may be a bacterium, a fungus or a virus.
- the microorganism that can cause sepsis may be a microorganism of the genus Streptococcus species and Enterococcus species belonging to Gram-positive bacteria, but is not limited thereto.
- the microorganism causing sepsis may be Staphylococcus pneumoniae or Staphylococcus aureus.
- it may be a genus Klebsiella, Pseudomonas species, or Enterobacter species belonging to Gram-negative bacteria, but is not limited thereto.
- the microorganism causing sepsis may be Escherichia coli, Vibrio vulnificus, or Hemophilus influenzae.
- the sepsis may be caused by lipopolysaccharides present in microorganisms.
- the sepsis is accompanied by an inflammatory response that appears upon exposure to a virus
- the virus is influenza virus, coronavirus, adenovirus, herpes simplex virus, measles.
- the virus may be in wild-type or mutated form.
- the virus may also be an oncolytic virus, for example a recombinant vaccinia virus in which the thymidine kinase (TK) gene is deleted.
- the oncolytic virus is as described above.
- active ingredient refers to an ingredient that exhibits activity alone or together with an adjuvant (carrier) that is inactive by itself.
- the pharmaceutical composition may further include an antibiotic or antiviral agent.
- the pharmaceutical composition may further include an antibiotic.
- the antibiotics are doripenem, cefepime, imipenem, meropenem, ceftazidime, ceftaroline fosamil, ceftriaxone, At least one selected from the group consisting of imipenem, vancomycin, teicoplanin, cefotaxime, metronidazole or aminoglycoside antibiotics and combinations thereof may, but is not limited thereto.
- the pharmaceutical composition may further include an antiviral agent.
- the antiviral agent is oseltamivir, zanamivir, peramivir, acyclovir, valacyclovir, famciclovir, trifluridine, lamivudine, telbivudine, clevudine, entecavir, adefovir, tenofovir disoproxil, te Nofovir alafenamide, besifovir, ribavirin, dasabuvir, sofosbuvir, daclatasvir, asunaprevir, zidovudine, abacavir, efavirenz, etravirine, nevirapine, rilpivirine, ata It may be at least one selected from the group consisting of zanavir, darunavir, nelifavir, ritonavir, indinabil, dolutegravir, raltegravil,
- the pharmaceutical composition may be administered with an antibiotic or antiviral agent in an amount of 0.1 mg/kg to 200 mg/kg once based on the body weight of the subject to be administered.
- the pharmaceutical composition is 0.1 mg/kg to 200 mg/kg, 1 mg/kg to 190 mg/kg, 5 mg/kg to 180 mg/kg, 10 mg/kg to 170 mg/kg 20 mg/kg
- An antibiotic or antiviral agent in an amount of kg to 160 mg/kg or 40 mg/kg to 150 mg/kg may be administered.
- the pharmaceutical composition may be formulated as an injection.
- injection refers to a solution, suspension, emulsion, or sterile preparation that is used by dissolving or suspending in a solvent when using, or a solution, suspension, or emulsion of a drug directly applied to the body through the skin or through the skin and mucous membranes.
- it may be used as an injection, powder injection, infusion, freeze-dried injection, transplant, long-acting injection, peritoneal dialysis agent, perfusion agent or dialysis agent.
- the injection may be administered by bolus, instillation, subcutaneous injection, or intramuscular injection.
- the compound in the injection may be dissolved in water for injection.
- the water for injection may be physiological saline injection, Ringel's solution or other aqueous solution.
- the compound may be dissolved in a non-aqueous solvent such as vegetable oil.
- the compound is 0.1 mg/ml to 100 mg/ml, 1 mg/ml to 90 mg/ml, 10 mg/ml to 80 mg/ml, 20 mg/ml to 70 mg/ml, 30 mg/ml in the injection. ml to 60 mg/ml, or 40 mg/ml to 50 mg/ml.
- the injection can be prepared as an injection that is physically and chemically very stable by adjusting the pH using a buffer solution such as an aqueous acid solution or phosphate that can be used as an injection in order to ensure product stability according to the distribution of the injection prescription.
- a buffer solution such as an aqueous acid solution or phosphate that can be used as an injection in order to ensure product stability according to the distribution of the injection prescription.
- the pharmaceutical composition may include water for injection.
- the water for injection means distilled water made to dissolve the solid injection or to dilute the water-soluble injection.
- the pharmaceutical composition may include a stabilizer or a solubilizing agent.
- the stabilizer may be sodium pyrosulfite or ethylenediaminetetraacetic acid
- the solubilizing agent may be hydrochloric acid, acetic acid, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate or potassium hydroxide.
- the pharmaceutical composition may further include other excipients commonly used for injection.
- Another aspect of the present invention provides a pharmaceutical composition for preventing, alleviating or treating neutrophilia, comprising the compound of Structural Formula 1 (hydroxyurea) or a pharmaceutically acceptable salt thereof as an active ingredient.
- neutrophilia refers to a condition in which neutrophilic granulocytes in the peripheral blood are increased more than normal.
- neutrophilia is acute infection, bacterial infection, malignancy, inflammation, tissue necrosis, bone marrow. It can occur due to proliferative diseases, etc., and can also occur when adrenaline or adrenocorticosteroids are administered.
- the neutropenia may be caused by an acute infection or bacterial infection, such as when the subject is exposed to microorganisms, particularly viruses.
- neutropenia may be accompanied when a systemic inflammatory response occurs, such as in systemic inflammatory syndrome or sepsis, due to exposure to a pathogenic virus such as influenza or coronavirus.
- the neutrophilia may occur upon exposure to bacteria or viruses.
- the neutrophilia may be induced by exposure to a virus for therapeutic purposes, such as an oncolytic virus.
- the neutropenia appears upon exposure to a virus, and the virus is influenza virus, coronavirus, adenovirus, herpes simplex virus, measles virus, Lentivirus, Retrovirus, Cytomegalovirus, Baculovirus, Reovirus, Adeno-associated virus, Myxoma virus, Vesicular stomatitis virus, Poliovirus, Newcastle disease virus, Parvovirus, Coxsackie virus, Senecavirus, Vaccinia virus ) or a poxvirus.
- influenza virus coronavirus
- adenovirus herpes simplex virus, measles virus, Lentivirus, Retrovirus, Cytomegalovirus
- Baculovirus Reovirus
- Adeno-associated virus Myxoma virus
- Vesicular stomatitis virus Poliovirus
- Newcastle disease virus Newcastle disease virus
- Parvovirus Coxsackie virus
- Senecavirus Senecavirus
- Vaccinia virus a poxvirus
- the virus may be in wild-type or mutated form.
- the virus may also be an oncolytic virus, for example a recombinant vaccinia virus in which the thymidine kinase (TK) gene is deleted.
- the oncolytic virus is as described above.
- the pharmaceutical composition according to the present invention for alleviating or treating neutropenia may also include an antibiotic or antiviral agent as exemplified above.
- the pharmaceutical composition according to the present invention for alleviating neutropenia may also be formulated as an injection.
- the injection and the compound form and concentration in the injection are as described above.
- the pharmaceutical composition may include a stabilizer or a solubilizing agent.
- the stabilizer may be sodium pyrosulfite or ethylenediaminetetraacetic acid
- the solubilizing agent may be hydrochloric acid, acetic acid, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate or potassium hydroxide.
- the pharmaceutical composition may further include other excipients commonly used for injection.
- the compound of Structural Formula 1 or a pharmaceutically acceptable salt thereof may be used together with a second active ingredient such as an antibiotic or antiviral agent.
- a first composition comprising a compound of the following Structural Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient;
- the first composition and the second composition may be administered in combination simultaneously, sequentially, or in reverse order. Specifically, the first composition and the second composition may be administered simultaneously. In addition, the first composition may be administered first, and then the second composition may be administered. Furthermore, the first composition may be administered after the second composition is first administered. In addition, the second composition may be administered first, then the first composition may be administered, and then the second composition may be administered again.
- the first composition and the second composition may be administered to a human or other mammal suffering from or suspected of having systemic inflammatory response syndrome, sepsis or neutrophilia.
- the first composition and the second composition may be an injection that can be administered intravenously, intramuscularly or subcutaneously.
- the first composition and the second composition are physically and chemically very stable injections by adjusting the pH using a buffer solution such as an aqueous acid solution or phosphate that can be used for injection in order to ensure product stability according to the distribution of the injection prescription.
- a buffer solution such as an aqueous acid solution or phosphate that can be used for injection in order to ensure product stability according to the distribution of the injection prescription.
- the first composition and the second composition may include water for injection.
- the water for injection means distilled water made to dissolve the solid injection or to dilute the water-soluble injection.
- the first composition and the second composition may include a stabilizer or a dissolution aid.
- the stabilizer may be sodium pyrosulfite or ethylenediaminetetraacetic acid
- the solubilizing agent may be hydrochloric acid, acetic acid, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate or potassium hydroxide.
- the compositions may further comprise other excipients conventionally used for injection.
- Another aspect of the present invention provides a method for preventing, alleviating or treating systemic inflammatory response syndrome, sepsis or neutropenia, comprising administering to a subject the aforementioned pharmaceutical composition.
- the subject may be a mammal, preferably a human.
- the administration may be intravenous (intra-venous), intra-muscular (intra-muscular) or intra-dermal (intra-dermal) administration.
- intravenous intra-venous
- intra-muscular intra-muscular
- intra-dermal intra-dermal
- the pharmaceutical composition according to the present invention when administered to an individual suffering from systemic inflammatory response syndrome, sepsis or neutrophilia, it can be used for alleviation or treatment of systemic inflammatory response by modulating immune cells.
- the step of administering an antibiotic or antiviral agent may be further included.
- the antibiotic used and the administration method are as described above.
- Another aspect of the present invention provides the use of the aforementioned pharmaceutical composition for the treatment of systemic inflammatory syndrome, sepsis or neutrophilia.
- Another aspect of the present invention provides the use of the aforementioned pharmaceutical composition for the manufacture of a medicament for the treatment of systemic inflammatory syndrome, sepsis or neutropenia.
- An injection containing hydroxyurea was prepared with the following composition.
- Injections including hydroxyurea and antibiotics were prepared with the following composition.
- An injection containing hydroxyurea and an antiviral agent was prepared with the following composition.
- Vaccinia virus Western Reserve species (Western Reserve, WR) is known as a virulent virus that propagates well in a syngeneic mouse model and has a high fatality rate.
- vaccinia virus WR strain (1 ⁇ 10 5 pfu or 1 ⁇ 10 7 pfu) was administered to the nasal mucosa to infect the sepsis. After induction, an animal experiment was performed. Mice were divided into a control group (WR), a group administered with G-CSF (WR+G-CSF (25 ⁇ g/kg)), and a group administered with hydroxyurea (WR+HU (50 mg/kg).
- the vaccinia virus WR strain used above was a recombinant vaccinia virus in which the thymidine kinase (TK) gene was deleted.
- TK thymidine kinase
- wild-type vaccinia virus Wyeth strain (NYC Department of Health) and WR strain were purchased from ATCC (American Type Culture Collection).
- ATCC American Type Culture Collection
- TK region of wild-type vaccinia virus was transcribed into a firefly luciferase reporter (p7).
- the shuttle plasmid having the .5 promoter) gene or the shuttle plasmid having the GFP gene were substituted using a vector.
- the control group and the G-CSF administration group all mice died before 14 days after administration of the vaccinia virus WR species ( FIGS. 4 and 5 ).
- mouse blood of the hydroxyurea-administered group was collected and the number of virus particles was measured.
- the number of virus particles was the highest in the hydroxyurea-administered group.
- the survival rate could be increased due to immune regulation rather than toxicity caused by the virus (FIG. 6).
- mice In relation to the survival rate of mice, the relationship between virus proliferation and neutrophil infiltration was confirmed through histological analysis.
- the group was divided into a control group (WR), a G-CSF administration group (WR+G-CSF (25 ⁇ g/kg)), and a hydroxyurea administration group (WR+HU (50 mg/kg), and wild-type vaccinia
- the conditions were the same except that the Nia virus WR strain (1 ⁇ 10 7 pfu) was administered to the nasal mucosa.
- the mice were sacrificed before death or immediately before death, and liver and lung tissues were collected.Normal mice without virus also One animal was sacrificed and used as a negative control.
- Tamiflu oseltamivir
- hydroxyurea known as representative antiviral agents, were administered alone or in combination to three groups infected with influenza A virus. Tamiflu was administered at a concentration of 0.1 mg/kg or 10 mg/kg, and hydroxyurea was administered at a concentration of 50 mg/kg (FIG. 8).
- mice in the group treated with influenza A virus only died on the 11th day, whereas mice in the three groups treated with Tamiflu survived regardless of the concentration.
- mice in the group treated with hydroxyurea alone two mice died on the 9th and 10th days, respectively, but the remaining 5 mice all survived (FIG. 9).
- mice in the group treated with influenza A virus only lost about 30% in body weight and died, and the weight of mice in the rest of the group decreased within 10%. It recovered and increased back to the initial body weight (FIG. 10).
- influenza viruses H1N1 PR8, H3N2 HongKong, Lee
- serum-free conditions 33°C to 35°C.
- the cells were washed with PBS, and MEM and TPCK-trypsin (2 ⁇ g/ml, Sigma) were added. After 72 hours, the cell viability by the virus was measured by MTT assay.
- the CC 50 of hydroxyurea was measured to be 1,561 ⁇ g/ml, but up to a concentration of 1,561 ⁇ g/ml, hydroxyurea was antiviral against influenza A (H1N1 PR8, H3N2 HongKong) and B (Lee) viruses. It was confirmed that the effect did not appear at all. On the other hand, Tamiflu (OSV-C) showed a specific antiviral effect on all three viruses, and the degree was ribavirin, followed by AMT.
- toxicity was evaluated through systemic inflammation and pustule incidence, body temperature measurement, and body weight measurement.
- the number of virus particles, absolute neutrophil count (ANC), whole blood cell (WBC), and absolute lymphocyte count (ALC) were calculated. measured.
- three mice were used in each of three subgroups for blood CBC, virus replication test, and histological examination. On days 1, 2 and 4, mice from the main group were sacrificed to obtain blood samples and Lung tissue was obtained.
- mice were divided into 2 groups (7 mice/group) as a post-hydroxyurea treatment group, and vaccinia virus WR species (1 ⁇ 10 5 pfu) was administered to the nasal mucosa and infected, after which 2 After one day, only one group was treated with hydroxyurea (80 mg/kg/day, 2-14 days).
- lung edema was observed in the lung tissue of the group treated with the vaccinia virus WR species and G-CSF rather than the lung tissue of the mouse in the group treated with only the vaccinia virus WR species.
- the cause of septic shock was due to other factors such as pro-inflammatory cytokines rather than cytotoxicity caused by pathogens.
- the lung tissue of the group treated with vaccinia virus WR species and hydroxyurea showed an improved pattern than that of the other group (FIG. 19, right).
- the lung tissue of the group treated with vaccinia virus WR species and hydroxyurea showed an improved pattern than that of the other group (FIG. 19, right).
- the first group was set as a negative control group not infected with the virus, and the second to fourth groups were infected by administering H1N1 influenza A virus (maPR8, 3XmlD50) to the nasal mucosa on day 0.
- the second group was set as a positive control group without any drug treatment, and the third and fourth groups were OSV-P (oseltamivir phosphate, 0.1 mg/kg, bid, 0 to 4 days) and hydroxyurea (50 mg/kg, respectively).
- OSV-P oseltamivir phosphate, 0.1 mg/kg, bid, 0 to 4 days
- hydroxyurea 50 mg/kg, respectively.
- Body weight and survival rate were measured up to day 20 at intervals of 5 days.
- the survival rate of the fourth group administered with hydroxyurea increased. Specifically, the mice in the second group, a positive control group, all died while losing weight until the 10th day, while the fourth group showed weight loss until the 10th day and recovered to the original weight on the 20th day, and 70% of the mice in the fourth group survived. (FIG. 20).
- the mice in the LPS+HU_30 group received hydroxyurea (30 mg/kg/day, from -1 to 3 days) once a day, and the mice in the LPS+HU_60 group received hydroxyurea (60 mg/kg/day) twice a day. mg/kg/day, from day -1 to day 3).
- the survival rate of each group was measured until the 12th day at 3-day intervals, and blood samples were collected on the 12th day to confirm the absolute neutrophil level in the blood.
- mice As a result, the group administered only LPS died within 24 to 48 hours. On the other hand, the survival rate of mice was significantly increased in the LPS+HU_30 and LPS+HU_60 groups. In addition, ANC was decreased in the LPS+HU_30 and LPS+HU_60 groups ( FIG. 21 ).
- VV tk- 1 ⁇ 10 8 pfu
- VV tk- and hydroxyurea VV
- toxicity was evaluated through systemic inflammation and pustule incidence, body temperature measurement, and body weight measurement.
- Vaccinia virus VV tk- with hydroxy urea is administered in combination VVtk - skin redness lesion was inhibited systemic inflammation are significantly weakened as compared to single administration group, such as pustules occurred (Fig. 22).
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (30)
- 제1항에 있어서,상기 전신성 염증 반응 증후군은 박테리아 또는 바이러스에 노출시 나타나는 염증 반응을 수반하는 것인 약학 조성물.
- 제2항에 있어서,상기 전신성 염증 반응 증후군은 바이러스에 노출시 나타나는 염증 반응을 수반하는 것이며, 상기 바이러스는 인플루엔자 바이러스(Influenza virus), 코로나바이러스(Coronavirus), 아데노바이러스(Adenovirus), 허피스 심플렉스 바이러스(Herpes simplex virus), 홍역 바이러스(Measles virus), 렌티바이러스(Lentivirus), 레트로바이러스(Retrovirus), 싸이토메갈로 바이러스(Cytomegalovirus), 배큘로바이러스(baculovirus), 리오바이러스(Reovirus), 아데노연관바이러스(Adeno-associated virus), 점액종 바이러스(Myxoma virus), 수포성 구내염 바이러스(Vesicular stomatitis virus), 폴리오바이러스(Poliovirus), 뉴캐슬병 바이러스(Newcastle disease virus), 파보바이러스(Parvovirus), 코사키 바이러스(Coxsackie virus), 세네카바이러스(Senecavirus), 백시니아 바이러스(Vaccinia virus) 및 폭스바이러스(Poxvirus)로 이루어지는 군으로부터 선택되는 하나 이상인 약학 조성물.
- [규칙 제91조에 의한 정정 14.04.2021]
제2항에 있어서, 상기 바이러스는 종양 용해 바이러스인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제1항에 있어서,상기 약학 조성물이 항생제 또는 항바이러스제를 추가적으로 더 포함하는 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제5항에 있어서,상기 항생제는 도리페넴(doripenem), 세페핌(cefepime), 이미페넴(imipenem), 메로페넴(meropenem), 세프타지딤(ceftazidime), 세프타롤린 포사밀(ceftaroline fosamil), 세프트리악손(ceftriaxone), 이미페넴(imipenem), 반코마이신(vancomycin), 테이코플라닌(teicoplanin), 세포탁심(cefotaxime), 메트로니다졸(metronidazole), 아미노글리코시드(aminoglycoside) 계열 항생제 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제5항에 있어서,상기 항바이러스제는 오셀타미비르, 자나미비르, 페라미비르, 아시클로버, 발라시클로비르, 팜시클로비르, 트리플루리딘, 라미부딘, 텔비부딘, 클레부딘, 엔테카비르, 아데포비어, 테노포비르 디소프록실, 테노포비르 알라페나미드, 베시포비르, 리바비린, 다사부비르, 소포스부비르, 다클라타스비르, 아수나프레비르, 지도부딘, 아바카비르, 에파비렌즈, 에트라비린, 네비라핀, 릴피비린, 아타자나비어, 다루나비르, 넬리파비르, 리토나비르, 인디나빌, 돌루테그라비르, 랄테그라빌, 엔푸버타이드, 마라비록 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제1항에 있어서,상기 약학 조성물이 주사제로 제형화된 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제9항에 있어서,상기 패혈증은 박테리아 또는 바이러스에 노출시 나타나는 염증 반응을 수반하는 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제10항에 있어서,상기 패혈증은 바이러스에 노출시 나타나는 염증 반응을 수반하는 것이며, 상기 바이러스는 인플루엔자 바이러스(Influenza virus), 코로나바이러스(Coronavirus), 아데노바이러스(Adenovirus), 허피스 심플렉스 바이러스(Herpes simplex virus), 홍역 바이러스(Measles virus), 렌티바이러스(Lentivirus), 레트로바이러스(Retrovirus), 싸이토메갈로 바이러스(Cytomegalovirus), 배큘로바이러스(baculovirus), 리오바이러스(Reovirus), 아데노연관바이러스(Adeno-associated virus), 점액종 바이러스(Myxoma virus), 수포성 구내염 바이러스(Vesicular stomatitis virus), 폴리오바이러스(Poliovirus), 뉴캐슬병 바이러스(Newcastle disease virus), 파보바이러스(Parvovirus), 코사키 바이러스(Coxsackie virus), 세네카바이러스(Senecavirus), 백시니아 바이러스(Vaccinia virus) 및 폭스바이러스(Poxvirus)로 이루어지는 군으로부터 선택되는 하나 이상인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제10항에 있어서,상기 바이러스는 종양 용해 바이러스인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제10항에 있어서,상기 약학 조성물이 항생제 또는 항바이러스제를 추가적으로 더 포함하는 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제13항에 있어서,상기 항생제는 도리페넴(doripenem), 세페핌(cefepime), 이미페넴(imipenem), 메로페넴(meropenem), 세프타지딤(ceftazidime), 세프타롤린 포사밀(ceftaroline fosamil), 세프트리악손(ceftriaxone), 이미페넴(imipenem), 반코마이신(vancomycin), 테이코플라닌(teicoplanin), 세포탁심(cefotaxime), 메트로니다졸(metronidazole), 아미노글리코시드(aminoglycoside) 계열 항생제 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제13항에 있어서,상기 항바이러스제는 오셀타미비르, 자나미비르, 페라미비르 , 아시클로버, 발라시클로비르, 팜시클로비르, 트리플루리딘, 라미부딘, 텔비부딘, 클레부딘, 엔테카비르, 아데포비어, 테노포비르 디소프록실, 테노포비르 알라페나미드, 베시포비르, 리바비린, 다사부비르, 소포스부비르, 다클라타스비르, 아수나프레비르, 지도부딘, 아바카비르, 에파비렌즈, 에트라비린, 네비라핀, 릴피비린, 아타자나비어, 다루나비르, 넬리파비르, 리토나비르, 인디나빌, 돌루테그라비르, 랄테그라빌, 엔푸버타이드, 마라비록 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제10항에 있어서,상기 약학 조성물이 주사제로 제형화된 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제17항에 있어서,상기 호중구증가를 박테리아 또는 바이러스에 노출시 나타나는 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제18항에 있어서,상기 호중구증가는 바이러스에 노출시 나타나는 것이며, 상기 바이러스는 인플루엔자 바이러스(Influenza virus), 코로나바이러스(Coronavirus), 아데노바이러스(Adenovirus), 허피스 심플렉스 바이러스(Herpes simplex virus), 홍역 바이러스(Measles virus), 렌티바이러스(Lentivirus), 레트로바이러스(Retrovirus), 싸이토메갈로 바이러스(Cytomegalovirus), 배큘로바이러스(baculovirus), 리오바이러스(Reovirus), 아데노연관바이러스(Adeno-associated virus), 점액종 바이러스(Myxoma virus), 수포성 구내염 바이러스(Vesicular stomatitis virus), 폴리오바이러스(Poliovirus), 뉴캐슬병 바이러스(Newcastle disease virus), 파보바이러스(Parvovirus), 코사키 바이러스(Coxsackie virus), 세네카바이러스(Senecavirus), 백시니아 바이러스(Vaccinia virus) 및 폭스바이러스(Poxvirus)로 이루어지는 군으로부터 선택되는 하나 이상인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제18항에 있어서,상기 바이러스는 종양 용해 바이러스인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제17항에 있어서,상기 약학 조성물이 항생제 또는 항바이러스제를 추가적으로 더 포함하는 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제21항에 있어서,상기 항생제는 도리페넴(doripenem), 세페핌(cefepime), 이미페넴(imipenem), 메로페넴(meropenem), 세프타지딤(ceftazidime), 세프타롤린 포사밀(ceftaroline fosamil), 세프트리악손(ceftriaxone), 이미페넴(imipenem), 반코마이신(vancomycin), 테이코플라닌(teicoplanin), 세포탁심(cefotaxime), 메트로니다졸(metronidazole), 아미노글리코시드(aminoglycoside) 계열 항생제 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제21항에 있어서,상기 항바이러스제는 오셀타미비르, 자나미비르, 페라미비르, 아시클로버, 발라시클로비르, 팜시클로비르, 트리플루리딘, 라미부딘, 텔비부딘, 클레부딘, 엔테카비르, 아데포비어, 테노포비르 디소프록실, 테노포비르 알라페나미드, 베시포비르, 리바비린, 다사부비르, 소포스부비르, 다클라타스비르, 아수나프레비르, 지도부딘, 아바카비르, 에파비렌즈, 에트라비린, 네비라핀, 릴피비린, 아타자나비어, 다루나비르, 넬리파비르, 리토나비르, 인디나빌, 돌루테그라비르, 랄테그라빌, 엔푸버타이드, 마라비록 및 이의 조합으로 이루어진 군에서 선택되는 적어도 어느 하나인 것인 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제17항에 있어서,상기 약학 조성물이 주사제로 제형화된 약학 조성물. - [규칙 제91조에 의한 정정 14.04.2021]
제1항의 약학 조성물을 개체에 투여하는 단계를 포함하는 전신성 염증 반응 증후군(systemic inflammatory response syndrome, SIRS)을 예방, 완화 또는 치료하는 방법. - [규칙 제91조에 의한 정정 14.04.2021]
제9항의 약학 조성물을 개체에 투여하는 단계를 포함하는 패혈증을 예방, 완화 또는 치료하는 방법. - [규칙 제91조에 의한 정정 14.04.2021]
제17항의 약학 조성물을 개체에 투여하는 단계를 포함하는 호중구증가증을 예방, 완화 또는 치료하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21753798.4A EP4104825A4 (en) | 2020-02-14 | 2021-02-15 | PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYUREA FOR INHIBITING THE INFLAMMATORY RESPONSE |
CA3167678A CA3167678C (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea |
US17/798,131 US20230096789A1 (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea |
CN202180009610.6A CN115279357A (zh) | 2020-02-14 | 2021-02-15 | 含有羟基脲的抑制炎症反应的药物组合物 |
AU2021221064A AU2021221064B2 (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea |
JP2022540957A JP7505160B2 (ja) | 2020-02-14 | 2021-02-15 | ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0018534 | 2020-02-14 | ||
KR1020200018534A KR102483232B1 (ko) | 2020-02-14 | 2020-02-14 | 히드록시유레아를 포함하는 패혈증 완화 또는 치료용 약학 조성물 |
KR10-2020-0044119 | 2020-04-10 | ||
KR1020200044119A KR102216319B1 (ko) | 2020-04-10 | 2020-04-10 | 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021162525A1 true WO2021162525A1 (ko) | 2021-08-19 |
Family
ID=77292458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/001910 WO2021162525A1 (ko) | 2020-02-14 | 2021-02-15 | 히드록시유레아를 포함하는 염증 반응 억제용 약학 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230096789A1 (ko) |
EP (1) | EP4104825A4 (ko) |
CN (1) | CN115279357A (ko) |
AU (1) | AU2021221064B2 (ko) |
CA (1) | CA3167678C (ko) |
WO (1) | WO2021162525A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7824691B2 (en) * | 2005-04-04 | 2010-11-02 | Centegen, Inc. | Use of RIP in treating staphylococcus aureus infections |
KR20190103979A (ko) * | 2018-02-28 | 2019-09-05 | 주식회사 바이오녹스 | 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
JP2020002167A (ja) * | 2013-11-08 | 2020-01-09 | アンチウイルス セラピューティクス | 敗血症を処置するための方法および組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3964219A4 (en) * | 2019-04-29 | 2022-07-06 | Paean Biotechnology Inc. | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SEPSIS OR SYSTEMIC INFLAMMATORY REACTION WITH ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT |
-
2021
- 2021-02-15 CA CA3167678A patent/CA3167678C/en active Active
- 2021-02-15 AU AU2021221064A patent/AU2021221064B2/en active Active
- 2021-02-15 CN CN202180009610.6A patent/CN115279357A/zh active Pending
- 2021-02-15 WO PCT/KR2021/001910 patent/WO2021162525A1/ko active Application Filing
- 2021-02-15 EP EP21753798.4A patent/EP4104825A4/en active Pending
- 2021-02-15 US US17/798,131 patent/US20230096789A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7824691B2 (en) * | 2005-04-04 | 2010-11-02 | Centegen, Inc. | Use of RIP in treating staphylococcus aureus infections |
JP2020002167A (ja) * | 2013-11-08 | 2020-01-09 | アンチウイルス セラピューティクス | 敗血症を処置するための方法および組成物 |
KR20190103979A (ko) * | 2018-02-28 | 2019-09-05 | 주식회사 바이오녹스 | 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (4)
Title |
---|
CAMILA BONONI ALMEIDA, LUCAS EDUARDO BOTELHO SOUZA, FLAVIA COSTA LEONARDO, FABIO TRINDADE MARANHA˜O COSTA, CLAUDIO C. WERNECK, DI: "Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea", BLOOD, vol. 126, no. 6, 1 May 2015 (2015-05-01), pages 711 - 720, XP055836887 * |
GEORGE ALEX, BENTON JENNIFER, PRATT JESSE, KIM MI-OK, KALINYAK KAREN A., KALFA THEODOSIA A., JOINER CLINTON H.: "The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease", PEDIATRIC BLOOD AND CANCER, WILEY, HOBOKEN, NJ, US, vol. 57, no. 4, 1 October 2011 (2011-10-01), US, pages 648 - 653, XP055836879, ISSN: 1545-5009, DOI: 10.1002/pbc.23030 * |
See also references of EP4104825A4 * |
TANG L.: "Clinical Effect and Therapeutic Drug Monitoring of Vancomycin Treatment on Neonatal Bacterial Sepsis", VALUE IN HEALTH, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 3, 1 January 1900 (1900-01-01), AMSTERDAM, NL, XP029218669, ISSN: 1098-3015, DOI: 10.1016/j.jval.2015.03.1337 * |
Also Published As
Publication number | Publication date |
---|---|
CA3167678C (en) | 2023-12-19 |
US20230096789A1 (en) | 2023-03-30 |
EP4104825A1 (en) | 2022-12-21 |
CN115279357A (zh) | 2022-11-01 |
EP4104825A4 (en) | 2023-12-20 |
AU2021221064B2 (en) | 2023-05-25 |
JP2023516539A (ja) | 2023-04-20 |
AU2021221064A1 (en) | 2022-09-01 |
CA3167678A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190309021A1 (en) | Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase | |
CN111346219B (zh) | 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途 | |
US20240093198A1 (en) | Tgf-beta therapeutics for age disease | |
WO2021162525A1 (ko) | 히드록시유레아를 포함하는 염증 반응 억제용 약학 조성물 | |
WO2020222483A1 (ko) | 분리된 미토콘드리아를 유효성분으로 포함하는 패혈증 또는 전신성 염증 반응 증후군 치료용 약학 조성물 | |
US8940867B2 (en) | Pan-antiviral peptides | |
JP7505160B2 (ja) | ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物 | |
US8198293B2 (en) | Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases | |
KR102216319B1 (ko) | 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형 | |
CN109700823B (zh) | 泰利霉素在抗埃博拉病毒感染中的应用 | |
CN1098687C (zh) | 氨基嘌呤抗病毒剂在治疗和预防潜伏性疱疹病毒感染中的用途 | |
US20220305092A1 (en) | Medicament and food for preventing or treating novel coronavirus pneumonia covid-19 and use thereof | |
CN111568900A (zh) | 吲哚美辛在抗冠状病毒感染中的应用 | |
WO2024005563A1 (ko) | 편도유래줄기세포를 유효성분으로 포함하는 감염성 폐 질환의 예방 또는 치료용 조성물 | |
WO2024019519A1 (ko) | iCP-NI를 포함하는 싸이토카인 폭풍 또는 염증성 질환의 치료 또는 예방용 약학적 조성물 | |
KR102483232B1 (ko) | 히드록시유레아를 포함하는 패혈증 완화 또는 치료용 약학 조성물 | |
CN112805027B (zh) | 一种抗新冠病毒感染的药物与应用 | |
US11161881B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
WO2024019496A1 (ko) | Icp-ni를 포함하는 covid-19 치료 또는 예방용 약학적 조성물 | |
WO2023048434A1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
CN116687932B (zh) | ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯的医药用途 | |
WO2023128427A1 (ko) | 폴리감마글루탐산을 유효성분으로 포함하는 코로나바이러스(sars-cov-2) 감염질환의 예방, 경감 또는 치료용 약학적 조성물 | |
CN112691094B (zh) | 防治病毒的新型化合物及其应用 | |
WO2024111897A1 (ko) | Prd-2001을 포함하는 암 예방 또는 치료용 약학적 조성물 | |
KR20050112127A (ko) | 중증급성호흡기증후군(sars)에 인터페론 베타 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21753798 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022540957 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3167678 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021221064 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2021221064 Country of ref document: AU Date of ref document: 20210215 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021753798 Country of ref document: EP Effective date: 20220914 |